← boardnext 2026-07-28next 2026-12next 2028-11-30
LTRN
Lantern Pharma Inc.distress 5/10 · elevated risk$2.73-4%today-49% from 52w high
Oncology 1
Lead: solid tumors · target PD-1
Revenue
pre-revenue
Liquidity
$19M
Runway
1.3 yrs
Shares 1y
+5%
Price & events
-22.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.9%
1D
-6.2%
1W
-28.7%
1M
+18.2%
3M
-21.1%
6M
-35.5%
1Y
-42.6%
2Y
-80.2%
5Y
-85.5%
All
Overview
- Market Cap
- $30.86M
- Volume
- 10.28K
- 52 Week Range
- $1.12 – $5.32
- Total Shares
- 11.30M
- Float Shares
- 9.59M
- Short %
- 7.31%
- % Held by Insiders
- 17.15%
- % Held by Institutions
- 14.16%
- RVOL
- 0.06x
- Beta
- 2.29
Pipeline stages · 3 programs
LP-184, Olaparib, Nivolumab & IpilimumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LP-300, Pemetrexed, Carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LP-284
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-28 Estimated 50% readout ~2026-09-11 final ~2027-01-31 | Phase 1/2 | LP-184, Olaparib, Nivolumab & Ipilimumabfast trackrare pediatric | Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation | 64 | active not recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | LP-300, Pemetrexed, Carboplatin | Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung | — | recruiting |
| 2028-11-30 Estimated 50% readout ~2028-12-30 | Phase 1 | LP-284orphan | Relapsed or Refractory Lymphomas, Advanced Solid Tumor | — | recruiting |
Catalyst news & presentations · 10
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- November 20, 2025 at 4:30 p.m. ETconferencedata presentationsecondaryPhase 1LP-184 · KOL-hosted scientific webinar on LP-184 Phase 1a resultsSEC 8-K
- Q3 2025trial initiationsecondaryLP-184 · Investigator-led exploratory clinical trial in DenmarkSEC 8-K
- Q3 2025readoutPhase 1LP-184 · Broader clinical data update with safety, PK, dose response and biomarker correlationsSEC 8-K
- Q3 2025readoutPhase 2LP-300 · Additional patient data readout from HARMONIC trial including Asian expansion cohortSEC 8-K
- end of June 2025enrollment completesecondaryPhase 1LP-184 · Completion of Phase 1a clinical trial enrollment with 62-65 patientsSEC 8-K
- Q2 2025readoutPhase 2LP-300 · Additional results from HARMONIC trial including expansion cohort data from Japan and Taiwan.SEC 8-K
- Q2 2025readoutPhase 1LP-184 · Broader clinical data update expected when enrollment finished.SEC 8-K
- 2025-05-05fda agreementLP-184 · FDA cleared Phase 1b/2 protocol for TNBC combination with Olaparib and monotherapySEC 8-K
- 2025-03-27fda agreementLP-184 · FDA raised no objections to Phase 1b/2 trial protocol in TNBC with Olaparib.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-04-02Lake StreetBuy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-23Lantern Pharma receives patent allowance for LP-184 biomarker test By Investing.com - Investing.com Canada
- 2026-07-23Three Genes Anchor Lantern Pharma's Newly Allowed LP-184 Patent - Stock Titan
- 2026-07-23Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers - Business Wire
- 2026-07-15Teva Celebrates the Pursuit of Adventure with New Performance and Lifestyle Footwear from its Fall 2026 Collection - Business Wire
- 2026-07-15Teva Celebrates the Pursuit of Adventure with New Performance and Lifestyle Footwear from its Fall 2026 Collection - Business Wire
- 2026-07-11New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group - ACCESS Newswire
- 2026-07-08$LTRN stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
- 2026-07-08Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.